Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
GERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.09 - $4.83
Previous CloseN/A
Volume1.63M
Average Volume (3M)10.20M
Market Cap
$893.22M
Enterprise Value$799.26M
Total Cash (Recent Filing)$387.98M
Total Debt (Recent Filing)$121.84M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 06, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding638,017,100
10 Day Avg. Volume6,748,843
30 Day Avg. Volume10,203,325
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue4.86
Enterprise Value/Gross Profit4.96
Enterprise Value/Ebitda-12.53
Forecast
1Y Price Target
$3.08Price Target Upside120.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Commercial StrategyGeron's strategic efforts are showing positive impact with broadening uptake through 400 new accounts and re-ordering among two-thirds of accounts.
LeadershipThe hiring of new CEO Harout Semerjian, who has extensive commercial leadership experience, is seen as a positive change.
Revenue PerformanceRytelo revenue in Q2 is not only a ~$2MM beat of expectations, but also an early signal of positive impact from the company's strategic efforts.
Bears Say
Demand TrendsManagement expressed confidence in their renewed commercial strategies, noting they are seeing increasing demand including in 1L/2L LR-MDS.
Inventory ImpactQ1 Rytelo sales of $39MM were impacted by inventory drawdown, but demand remained flat.
Sales PerformanceGeron reported Q1 Rytelo net sales of $39MM, which is below the estimate of $49MM and consensus of $48MM.
Geron News
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.09 and its highest was $4.83 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $893.22M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 06, 2025 which is in 67 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 06, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.029 by $0.009.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 638,017,100 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.029. Following the earnings report the stock price went up 15.833%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.08 (120.00% Upside)
$3.08 (120.00% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 286.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.29%
12-Months-Change
Fundamentals
Return on Equity
-31.09%
Trailing 12-Months
Asset Growth
23.54%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation (GERN) is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. The company specializes in telomere biology and is primarily engaged in the research and development of drugs that target telomerase, an enzyme that plays a crucial role in cancer cell immortality. Geron's lead product candidate, imetelstat, is an investigational telomerase inhibitor being studied for its potential to treat hematologic malignancies, particularly myelofibrosis and acute myeloid leukemia.
GERN Company Deck
GERN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance for RYTELO with significant revenue growth, team expansion, and promising clinical trial progress. However, challenges remain in data accuracy for patient usage, drug retention issues, and European commercialization uncertainties.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$3.08
▲(120.00% Upside)
Technical Analysis
Ownership Overview
0.10% Insiders
12.07% Mutual Funds
39.43% Other Institutional Investors
34.53% Public Companies and
Individual Investors